NCT01363128View on ClinicalTrials.gov

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 12, 2011

Primary Completion Date

April 8, 2020

Study Completion Date

April 8, 2020

Conditions
Acute Lymphoblastic LeukemiaAdult Acute Lymphoblastic Leukemia in Complete RemissionBurkitt LeukemiaBurkitt LymphomaCD20 PositiveChildhood Acute Lymphoblastic Leukemia in Complete RemissionLymphoblastic Lymphoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Dexamethasone

Given IV or PO

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Methotrexate

Given IV

BIOLOGICAL

Ofatumumab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01363128 - Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Biotech Hunter | Biotech Hunter